top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

PUBLICATIONS

Click links below for a full list of publications

The current landscape of nucleic acid therapeutics.

Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. 

Nat Nanotechnol. 2021; doi.org/10.1038/s41565-021-00898-0.

Prosaposin mediates inflammation in atherosclerosis.

van Leent MMT, Beldman TJ, Toner YC, Lameijer MA, Rother N, Bekkering S, Teunissen AJP, Zhou X, van der Meel R, Malkus J, Nauta SA, Klein ED, Fay F, Sanchez-Gaytan BL, Pérez-Medina C, Kluza E, Ye YX, Wojtkiewicz G, Fisher EA, Swirski FK, Nahrendorf M, Zhang B, Li Y, Zhang B, Joosten LAB, Pasterkamp G, Boltjes A, Fayad ZA, Lutgens E, Netea MG, Riksen NP, Mulder WJM, Duivenvoorden R. 

Sci Transl Med. 2021; doi.org/10.1126/scitranslmed.abe1433.

A modular approach toward producing nanotherapeutics targeting the innate immune system.

van Leent MMT, Meerwaldt AE, Berchouchi A, Toner YC, Burnett ME, Klein ED, Verschuur AVD, Nauta SA, Munitz J, Prévot G, van Leeuwen EM, Ordikhani F, Mourits VP, Calcagno C, Robson PM, Soultanidis G, Reiner T, Joosten RRM, Friedrich H, Madsen JC, Kluza E, van der Meel R, Joosten LAB, Netea MG, Ochando J, Fayad ZA, Pérez-Medina C, Mulder WJM, Teunissen AJP. 

Sci Adv. 2021; doi.org/10.1126/sciadv.abe7853.

Roadmap on nanomedicine.

Decuzzi P, Peer D, Mascolo DD, Palange AL, Manghnani PN, Moghimi SM, Farhangrazi ZS, Howard KA, Rosenblum D, Liang T, Chen Z, Wang Z, Zhu JJ, Gu Z, Korin N, Letourneur D, Chauvierre C, van der Meel R, Kiessling F, Lammers T.

Nanotechnology. 2021; doi.org/10.1088/1361-6528/abaadb.

EVQuant; high-throughput quantification and characterization of extracellular vesicle (sub)populations.

Hartjes TA, Slotman JA, Vredenbregt MS, Dits N, van der Meel R, Duijvesz D, Kulkarni JA, French PJ, Van Cappellen WA, Schiffelers RM, Houtsmuller AB, Jenster GW, Van Royen ME.

bioRxiv. 2020; doi.org/10.1101/2020.10.21.348375.

Dexamethasone nanomedicines for COVID-19.

Lammers T, Sofias AM, van der Meel R, Schiffelers R, Storm G, Tacke F, Koschmieder S, Brümmendorf TH, Kiessling F, Metselaar JM. 

Nat Nanotechnol. 2020; doi.org/10.1038/s41565-020-0752-z.

Quantitative imaging approaches facilitating nanomedicine translation.

Pérez-Medina C, Teunissen AJP, Kluza E, Mulder WJM, van der Meel R. 

Adv Drug Deliv Rev. 2020; doi.org/10.1016/j.addr.2020.07.017.

Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency

Strilchuk AW, Meixner SC, Leung J, Safikhan NS, Kulkarni JA, Russell HM, van der Meel R, Sutherland MR, Owens III AP, Conway EM, Pryzdial ELG, Cullis PR, Kastrup CJ

Blood. 2020; doi.org/10.1182/blood.2020004976.

Lipid nanoparticle technology for therapeutic gene regulation in the liver.

Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R.

Adv Drug Deliv Rev. 2020; doi.org/10.1016/j.addr.2020.06.026.

Nanotechnology for organ-tunable gene editing.

Van der Meel R.

Nat Nanotechnol. 2020; doi.org/10.1038/s41565-020-0666-9. 

Cancer nanomedicine meets immunotherapy: Opportunities and challenges.

Sun Q, Bai X, Sofias AM, van der Meel R, Ruiz-Hernandez E, Storm G, Hennink WE, De Geest B, Kiessling F, Yu H, Lammers T, Shi Y.

Acta Pharmacol Sin. 2020; doi.org/10.1038/s41401-020-0448-9.

Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery.

Van der Meel R,  Chen S, Zaifman J,  Kulkarni JA, Zhang XRS, Tam YK, Bally MB, Schiffelers RM, Ciufolini MA,  Cullis PR, Tam YYC.

bioRxiv 2020; doi.org/10.1101/2020.01.16.907394.

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.

Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR.

Nat Nanotechnol. 2019; doi.org/10.1038/s41565-019-0591-y.

Smart Cancer Nanomedicine.

Van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T.

Nat Nanotechnol. 2019; doi.org/10.1038/s41565-019-0567-y.

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.

Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R.

Acc Chem Res. 2019; doi.org/10.1021/acs.accounts.9b00368.

Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads.

Kulkarni JA, Witzigmann D, Leung J, van der Meel R, Zaifman J, Darjuan MM, Grisch-Chan HM, Thöny B, Tam YYC, Cullis PR.

Nanoscale. 2019; doi.org/10.1039/c9nr02004g.

On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.

Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, Tam YYC, Cullis PR.

ACS Nano. 2018; doi.org/10.1021/acsnano.8b01516. 

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery.

Evers MJW, Kulkarni JA, van der Meel R, Cullis PR, Vader P, Schiffelers RM. 

Small Methods. 2018; doi.org/10.1002/smtd.201700375.

In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System.

Borgheti-Cardoso LN, Kooijmans SAA, Fens MHAM, van der Meel R, Vicentini FTMC, Fantini MCA, Bentley MVLB, Schiffelers RM.

Mol Pharm. 2017; doi.org/10.1021/acs.molpharmaceut.6b01141. 

Cancer nanomedicines: oversold or underappreciated?

Van der Meel R, Lammers T, Hennink WE.

Expert Opin Drug Deliv. 2017; doi.org/10.1080/17425247.2017.1262346.

The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.

Wang H, Tam YY, Chen S, Zaifman J, van der Meel R, Ciufolini MA, Cullis PR.

Mol Ther. 2016; doi.org/10.1038/mt.2016.179. 

Cetuximab treatment alters the content of extracellular vesicles released from tumor cells.

van Dommelen SM, van der Meel R, van Solinge WW, Coimbra M, Vader P, Schiffelers RM.

Nanomedicine (Lond). 2016; doi.org/10.2217/nnm-2015-0009. 

PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time.

Kooijmans SAA, Fliervoet LAL, van der Meel R, Fens MHAM, Heijnen HFG, van Bergen En Henegouwen PMP, Vader P, Schiffelers RM.

J Control Release. 2016; doi.org/10.1016/j.jconrel.2016.01.009. 

An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs.

Borgheti-Cardoso LN, Depieri LV, Kooijmans SA, Diniz H, Calzzani RA, Vicentini FT, van der Meel R, Fantini MC, Iyomasa MM, Schiffelers RM, Bentley MV.

Eur J Pharm Sci. 2015; doi.org/10.1016/j.ejps.2015.04.017.

Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles.

Shi Y, van der Meel R, Theek B, Oude Blenke E, Pieters EH, Fens MH, Ehling J, Schiffelers RM, Storm G, van Nostrum CF, Lammers T, Hennink WE.

ACS Nano. 2015; doi.org/10.1021/acsnano.5b00929.

Extracellular vesicles as drug delivery systems: lessons from the liposome field.

Van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM.

J Control Release. 2014; doi.org/10.1016/j.jconrel.2014.07.049.

Tumour-targeted nanobullets for cancer treatment [Tumorgerichte nanobullets voor kankertherapie]. 

Van der Meel R.

Pharmaceutisch Weekblad Wetenschappelijk Platform. 2014;8:a1421 (Article in Dutch).

Toward routine detection of extracellular vesicles in clinical samples.

Van der Meel R, Krawczyk-Durka M, van Solinge WW, Schiffelers RM.

Int J Lab Hematol. 2014; doi.org/10.1111/ijlh.12247.

Capillary electrophoresis-based assessment of nanobody affinity and purity.

Haselberg R, Oliveira S, van der Meel R, Somsen GW, de Jong GJ.

Anal Chim Acta. 2014; doi.org/10.1016/j.aca.2014.01.048. 

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.

Van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV.

Adv Drug Deliv Rev. 2013; doi.org/10.1016/j.addr.2013.08.012. 

Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.

Van der Meel R, Oliveira S, Altintas I, Heukers R, Pieters EH, van Bergen en Henegouwen PM, Storm G, Hennink WE, Kok RJ, Schiffelers RM.

Mol Pharm. 2013; doi.org/10.1021/mp400212v.

Targeted inhibition of tumor growth and angiogenesis.

Van der Meel R.

Utrecht University, 2013, Thesis, ISBN 978-94-6203-377-1.  

Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.

Altintas I, Heukers R, van der Meel R, Lacombe M, Amidi M, van Bergen En Henegouwen PM, Hennink WE, Schiffelers RM, Kok RJ.

J Control Release. 2013 Jan 28;165(2):110-8. 

Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.

Van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, van Bergen en Henegouwen PM, Storm G, Hennink WE, Schiffelers RM, Kok RJ.

J Control Release. 2012 Apr 30;159(2):281-9. 

Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.

Vader P, Crielaard BJ, van Dommelen SM, van der Meel R, Storm G, Schiffelers RM.

J Control Release. 2012 Jun 10;160(2):211-6. 

Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach.

Vader P, van der Meel R, Symons MH, Fens MH, Pieters E, Wilschut KJ, Storm G, Jarzabek M, Gallagher WM, Schiffelers RM, Byrne AT.

Angiogenesis. 2011 Dec;14(4):457-66.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

Van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. 

Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting.

Talelli M, Rijcken CJ, Oliveira S, van der Meel R, van Bergen En Henegouwen PM, Lammers T, van Nostrum CF, Storm G, Hennink WE.

J Control Release. 2011 Apr 30;151(2):183-92. 

Downregulation of EGFR by a novel multivalent nanobody-liposome platform.

Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, Storm G, Roovers RC.

J Control Release. 2010 Jul 14;145(2):165-75.

Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.

Van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT.

Drug Discov Today. 2010 Feb;15(3-4):102-14.

bottom of page